Table of Contents Table of Contents
Previous Page  19 / 27 Next Page
Information
Show Menu
Previous Page 19 / 27 Next Page
Page Background

Inmunoterapia en segunda línea CPNCP

Fármaco

Mec. acción

Ensayos

PD-L1

Nivolumab

Anti-PD-1

Checkmate 017 (SqCC)

Dako 28.8 (all

comers)

Checkmate 057 (Non-SqCC)

CA209-003 (fase 1 NSCLC)

Pembrolizumab

Anti-PD-1

Keynote 001 (fase 1 NSCLC)

Dako 22C3 (≥1%)

Keynote 010

Atezolizumab

Anti-PD-L1

POPLAR (fase 2)

Ventana SP142 (TC

and IC) (all comers)

OAK